Featured Research

from universities, journals, and other organizations

Fear feeds the pain: Suffering from lumbago

Date:
October 17, 2013
Source:
Schweizerischer Nationalfonds zur Foerderung der wissenschaftlichen Forschung
Summary:
People suffering from lumbago do not move as healthy people do. The pain and the fear of it change their way of moving. This partially explains how acute lumbago can in some cases become chronic. A researcher has shown that patients suffer less if they are reassured.

People suffering from lumbago do not move as healthy people do. The pain and the fear of it change their way of moving. This partially explains how acute lumbago can in some cases become chronic. A researcher supported by the Swiss National Science Foundation has shown that patients suffer less if they are reassured.

According to the statistics, only 20% of the population in industrialised countries maintain that they have never experienced back pain. The majority of people suffer at least once in their lives from lumbago, an affliction characterised by pain between the twelfth rib and the buttocks crease. Lumbago is mainly caused by the manipulation of heavy objects, bad posture, stress or a lack of physical activity.

Patients generally recover within six to twelve weeks. However, for reasons that are still unknown, the illness becomes chronic and the prospects of recovery uncertain for a minority of the patients. The treatment of such patients accounts for 85% of the total costs incurred by cases of lumbago, i.e. approximately CHF 6 billion per year in Switzerland.

Yves Henchoz and his colleagues at the University of Quebec in Trois-Rivi่res, Canada, wondered what role the fear of pain might play in the chronification of the illness: does fear change the activity of the trunk muscles and the way in which movements are executed? They asked 22 people in good health and 22 patients suffering from chronic lumbago to bend and then straighten their trunks. While the participants were doing this, a thermode was applied to their lower back; the thermode issued three levels of heat: painless, slightly painful or painful. Before each contact, the participants were informed about the stimulation that they were about to receive.

A vicious circle During the experiment, the researchers measured the movements of the lower back and the lumbar muscle activity. The -- recently published -- results were surprising. People in good health are most influenced by the fear of pain: the stronger the fear, the more rigid the muscles become. In patients suffering from chronic lumbago, the anticipation of strong pain leads to less neuromuscular change. The researchers' explanation is that these patients are already stiff when they bend their backs and receive the painless heat. As their movement strategy is more fixed, it adapts less well to the environment. They are trapped within a vicious circle: fearing the suffering linked to movement, they lose their mobility, and the pain persists.

Manipulating the waits Six out of the 27 times that the participants bent and straightened their backs, the researchers manipulated their anticipation of the pain through false instructions: before applying a high level of heat, they announced only a slight pain. Both the persons in good health and those suffering from lumbago felt less pain when the hot thermode was applied. Hence, it seems that the first pain-reliever to be administered to a patient suffering from acute lumbago should be a generous dose of reassuring words, in order to prevent the illness from becoming chronic.


Story Source:

The above story is based on materials provided by Schweizerischer Nationalfonds zur Foerderung der wissenschaftlichen Forschung. Note: Materials may be edited for content and length.


Journal Reference:

  1. Yves Henchoz, Charles T้treau, Jacques Abboud, Mathieu Pich้, Martin Descarreaux. Effects of noxious stimulation and pain expectations on neuromuscular control of the spine in patients with chronic low back pain. The Spine Journal, 2013; DOI: 10.1016/j.spinee.2013.07.452

Cite This Page:

Schweizerischer Nationalfonds zur Foerderung der wissenschaftlichen Forschung. "Fear feeds the pain: Suffering from lumbago." ScienceDaily. ScienceDaily, 17 October 2013. <www.sciencedaily.com/releases/2013/10/131017080104.htm>.
Schweizerischer Nationalfonds zur Foerderung der wissenschaftlichen Forschung. (2013, October 17). Fear feeds the pain: Suffering from lumbago. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2013/10/131017080104.htm
Schweizerischer Nationalfonds zur Foerderung der wissenschaftlichen Forschung. "Fear feeds the pain: Suffering from lumbago." ScienceDaily. www.sciencedaily.com/releases/2013/10/131017080104.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins